What is Cullgen?
Founded in 2018, Cullgen is at the forefront of developing first-in-class new chemical entities (NCEs) designed to treat diseases that currently lack effective therapeutic options. The company's core competency lies in its proprietary ubiquitin-mediated, small molecule-induced target elimination technology. By leveraging recent scientific breakthroughs in protein degradation, Cullgen is positioning itself to disrupt traditional drug discovery paradigms.
The company operates at the intersection of advanced molecular biology and medicinal chemistry, focusing on the precise removal of disease-causing proteins. This specialized approach has attracted significant attention from global healthcare entities and venture capital firms, validating the potential of their platform to deliver high-impact medical solutions.
How much funding has Cullgen raised?
Cullgen has raised a total of $106M across 3 funding rounds:
Series A
$16M
Series B
$50M
Series C
$40M
Series A (2019): $16M, investors not publicly disclosed
Series B (2021): $50M led by Octagon Capital, South China Venture Capital, Height Capital Management, 3E Bioventures Capital, and MSA Capital
Series C (2023): $40M supported by GNI Group, AstraZeneca, and Wuxi Venture Capital Group
Key Investors in Cullgen
GNI Group
GNI Group is a global healthcare company headquartered in Japan, focused on drug discovery and manufacturing to address unmet medical needs through its unique platform.
AstraZeneca
AstraZeneca is a leading global biopharmaceutical company based in the United Kingdom, specializing in the discovery and commercialization of prescription medicines across oncology and other therapeutic areas.
Wuxi Venture Capital Group
Wuxi Venture Capital Group is a government-backed investment institution that provides critical financing support to high-tech startups and technology-driven enterprises.
What's next for Cullgen?
With the recent infusion of capital, Cullgen is well-positioned to accelerate its pipeline development and expand its clinical research capabilities. The strategic backing from global healthcare leaders and venture firms provides not only the necessary financial runway but also access to extensive networks for drug commercialization and international market entry.
Looking ahead, the company is expected to focus on scaling its drug discovery operations and advancing its lead candidates through the regulatory pipeline. As Cullgen continues to refine its protein degradation platform, the focus will likely shift toward establishing further partnerships and potentially initiating clinical trials, solidifying its role as a critical innovator in the global biopharmaceutical sector.
